Assembly Biosciences provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024. By mid-year 2024: ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor targeting recurrent genital herpes, is expected to enter a first-in-human clinical study; and ABI-4334, a highly potent next-generation capsid assembly modulator, is anticipated to enter a Phase 1b study in chronic hepatitis B virus patients. By the end of 2024: Two additional candidates are anticipated to enter the clinic: ABI-1179, the long-acting HSV helicase-primase inhibitor contributed by Gilead under the collaboration between Assembly Bio and Gilead; and ABI-6250, a small molecule orally-bioavailable hepatitis delta virus entry inhibitor. Initial clinical data are expected to be available from both the ABI-5366 first-in-human clinical study and the ABI-4334 Phase 1b study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ASMB:
- Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Assembly Biosciences presents new data on viral hepatitis portfolio
- Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
- Assembly Biosciences names Gaggar as Chief Medical Officer
- Is ASMB a Buy, Before Earnings?
